ePrints

Antibody decay, T cell immunity and breakthrough infections following two SARS-CoV-2 vaccine doses in 1 inflammatory bowel disease patients treated with infliximab and vedolizumab

Lookup NU author(s): Professor Chris LambORCiD

Downloads

• Accepted version [.pdf]

Licence

This work is licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0).

Publication metadata

Author(s): Lin S, Kennedy NA, Saifuddin A, Muñoz Sandoval D, Reynolds CJ, Castro Seoane R, Kottoor SH, Pieper FP, Lin K-M, Butler DK, Chanchlani N, Nice R, Chee D, Bewshea C, Janjua M, McDonald TJ, Sebastian S, Alexander JL, Constable L, Lee JC, Murray CD, Hart AL, Irving PM, Jones G-R, Kok KB, Lamb CA, Lees CW, Altmann DM, Boyton RJ, Goodhand JR, Powell N, Ahmad T

Publication type: Article

Publication status: Published

Journal: Nature Communications

Year: 2022

Volume: 13

Online publication date: 16/03/2022

Acceptance date: 26/01/2022

Date deposited: 26/01/2022

ISSN (electronic): 2041-1723

Publisher: Nature Publishing Group

URL: https://doi.org/10.1038/s41467-022-28517-z

DOI: 10.1038/s41467-022-28517-z

PubMed id: 35296643

Altmetrics

Funding

Share